Last reviewed · How we verify
Galcanezumab-Gnlm
At a glance
| Generic name | Galcanezumab-Gnlm |
|---|---|
| Also known as | EMGALITY |
| Sponsor | Albany Medical College |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Effect of Galcanezumab-gnlm on Post-Traumatic, Migrainous Headaches (PHASE4)
- Tandem OnabotulinumtoxinA Galcanezumab Emerging Therapeutic Headache Elimination Research Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Galcanezumab-Gnlm CI brief — competitive landscape report
- Galcanezumab-Gnlm updates RSS · CI watch RSS
- Albany Medical College portfolio CI